COMMUNIQUÉS West-GlobeNewswire

Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance
12/01/2026
Inspire Announces Appointment of Matt Osberg as Executive Vice President and Chief Financial Officer Joining the Company in the First Quarter of 2026 MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical [...]
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
12/01/2026
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or [...]
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
12/01/2026
Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan [...]
Teladoc Health Launches Enhanced 24/7 Care Service
12/01/2026
New capabilities enable Teladoc Health’s care teams to address a broader spectrum of health needs, delivering more value in virtual urgent care visits NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: [...]
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
12/01/2026
Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and [...]
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
12/01/2026
Company to present at the 44th Annual JP Morgan Healthcare Conference FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced [...]
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
12/01/2026
Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patients Teizeild [...]
Communiqué de presse : Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2
12/01/2026
Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2 Approbation basée sur l’étude de phase 2 TN-10 qui a démontré un retard significatif dans l’apparition du DT1 de stade 3 [...]
Publication relating to transparency notification
12/01/2026
REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026 , 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2007 on the [...]
Publication relative à une notification de transparence
12/01/2026
INFORMATION RÉGLEMENTÉE Publication relative à une notification de transparence Mont-Saint-Guibert (Belgique), le 12 janvier 2026 , 7:00h CET / 1:00h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
12/01/2026
Allschwil, Switzerland – January 12, 2026 Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, [...]
Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America
12/01/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pharmacy in North [...]
argenx Highlights 2026 Strategic Priorities
12/01/2026
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on [...]
Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
12/01/2026
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effect The company [...]
Healthy Gut Announces Updated Holozyme Formula Addressing Digestive Sensitivity to Fructan-Containing Foods
12/01/2026
Boulder, CO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Healthy Gut, a Boulder-based digestive health company, announced the release of an updated formulation of its Holozyme product, reflecting the company’s expanded focus on [...]
FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation
12/01/2026
White Oak, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control ( [...]
Paul Chua Joins Health-ISAC® as Asia Pacific Operations Director
12/01/2026
Chua will spearhead Health-ISAC’s expansion into the APAC region, enhancing cybersecurity and resilience in the global health sector SINGAPORE, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis [...]
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
12/01/2026
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) TEL AVIV, Israel, Jan. 11, [...]
Zymeworks Outlines Strategic Priorities and Outlook for 2026
12/01/2026
Positive Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma ( GEA) presented at ASCO GI Up to $440.0 million in milestone payments [...]

Pages